The synthesis and purification of radiolabelled immunoconjugates, composed of a human IgM monoclonal antibody directed against an int~cellular tumour-as~ciated antigen and either poly ( CY-L&I-tamic acid) (PGA) or poly [ N5-( 2-hydroxyethyl)-L-~utamine] (PHEG) is described. Coupling of polymers to the antibody was performed through disulfide bond formation involving a single thiol group at the C-terminus of the polymer chain and 2-pyridyldisullide groups introduced onto the antibody. The antibody was iodinated with 13'1 before conjugation. The polymers contained tyrosinamide in a low degree of substitution and were radiolabelled with 12% '2SI-labelled PGA and PHEG were found to be stable for at least 3 days in murine and human plasma. The bio~st~bution in mice of the doubly labelled immunoconjugates was studied and was compared with the pharmacokinetics of the individual components.
Introduction
The targeting of drugs, radioisotopes and toxins with the aid of monoclonal antibodies ( MoAbs ) directed against tumor-associated antigens is an intensively studied strategy in the treatment of cancer [ l-3 1. The vast majority of
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antibodies employed in clinical investigations are MoAbs of murine origin. Most studies in which repetitive administration of immunoconjugates of these MoAbs was applied were hampered by the development of a human anti-mouse antibody {HAMA) response [ 11. Recently, large quantities of human MoAbs have become available through immunisation of cancer patients with autologous tumour cells (active specific immunotherapy, ASI) and subsequent immortalisation of their peripheral blood l~phoc~es [ 4,5 1 . They can be administered to humans in gram amounts without evoking an immune response or other undesirable side effects [ 4,5 1. A human IgM resulting from this AS1 programme designated as 16.88 is being studied extensively as a targeting vehicle in radio-and chemo-immunotherapy [ 4,5 1. It reacts with an intracellular tumour-associated antigen with an apparent molecular mass of 1 O3 kDa on high performance size-exclusion chromatography (HP-SEC ) and around 40 kDa on polyacrylamide gel electrophoresis in the presence of sodium dodecylsulphonate (SDS-PAGE) [ 61. MoAbs to intracellular antigens like IgM 16.88 home to necrotic areas in the tumour, which results in excellent images with y-emitting isotopes [ 
41.
From a theoretical point of view large amounts of chemo-immunoconjugates with a molar drug/ antibody ratio of at least 50 are needed for an effective tumour regression in case ADR is used as the cytostatic drug of choice [ 11. Since antibodies of the IgM type are extremely susceptible to chemical substitution, the use of intermediate drug carriers is a prerequisite in order to achieve the appropriate drug load of the immunoconjugate without affecting solubility and immunoreactivity of the targeting vehicle [ 1, 7] . In the literature various macromolecular compounds have been investigated for application as intermediate drug carrier, viz. natural proteins like serum albumin, polysaccharides and synthetic polymers like poly (cu-L-glutamic acid), PGA [ 3,7 1. PGA is biodegradable, non-immunogenic and non-toxic [ 8, 9] and it allows the binding of drugs via enzymatically or hydrolytically labile bonds [ 3, . Until now, no data on the biodistribution of PGA and immunoconjugates of this polymer were available. The pharmacokinetic properties of PGA may be completely determined by its polyanionic character, which may result in a preferential uptake by RES organs as was observed for the polycarboxylic acid prepared from the copolymer of divinylether and maleic anhydride (pyran copolymer) [ PHEG [ 14, 16, 17] , may be a better alternative.
In this paper the preparation and fractionation of PGA and PHEG and immunoconjugates of these polymers with the human MoAb 16.88 are described. The biodistribution in mice of immunoconjugates consisting of '251-labelled polymers and ' 31 I-labelled antibody was investigated and was compared with the pharmacokinetics of the parent components. The implication of the results on the use of PGA and PHEG as intermediate drug carriers in passive immunotherapy will be discussed.
Materials
THF and dioxane were refluxed overnight and distilled in the presence of sodium wire and benzophenone as an indicator. This procedure was repeated until development of a dark-blue color, indicating the absence of water. DMF was distilled in vacua and used immediately. N-ethylmorpholine and triethylamine were distilled from KOH. TFA was distilled.
The following compounds were obtained from the manufacturer indicated and were used as supplied. 2-aminoethanol, Merck, F.R.G.; anisole, Merck, F.R.G.; CDI, Merck, F.R.G.; DTT, Merck, F.R.G.; EEDQ, Serva, F.R.G.; ME, Merck, F.R.G.; MSA, Merck, F.R.G.; SPDP, Pierce, U.S.A.; TPS, Pharmacia, Sweden; triphosgene, Janssen, Belgium; TyrNH,, Serva, F.R.G. BLG was prepared as described [ 181. Cystamine free base was prepared from the dihydrochloride (Janssen, Belgium) as described
1191.
Buffers were prepared from analytical grade salts, filtered and deaerated with nitrogen. Buffer I, 0.10 M NaCl, 0.10 M sodium phosphate, pH 7.5; buffer II, 0.14 M NaCl, 0.05 M Tris-HCl, pH 8.0; buffer III, 0.10 M Tris-HCl, 1 mM EDTA, pH 8.5; buffer IV, 0.01 M sodium phosphate, 1 mM EDTA, pH 7.5; buffer V, 0.10 M sodium phosphate, 1 mM EDTA, pH 6.0; buffer VI, 0.10 M sodium phosphate, 1 mM EDTA, pH 7.0; buffer VII, 0.40 M sodium phosphate, 1 mM EDTA, pH 7.5.
Methods

Analytical procedures
'H NMR spectra were recorded on a Bruker WP 80 ( 80 MHz). TLC was performed on silica coated on plastic sheets 60 F254 (Merck, F.R.G. ) using the solvent systems chloroform/metha= nol/acetic acid (85/10/5; v/v) or n-butanol/ acetic acid/water (4/ l/ 1; v/v). Spots were visualized under UV-light or by spraying with ninhydrin solution (Merck, F.R.G.) followed by heating for 5-l 0 min at 110°C for detection of amino groups,
The content of PDT groups in polymeric conjugates, PDT-activated proteins and TPS was calculated from the increase in absorbance at 343 nm due to release of 2-pyridinethione upon reduction of the compound in buffer VI with 5-15 mM DTT for l-2 h at room temperature using a molar absorbance coefficient of 8080 M-' *cm-' [20 J. IgM concentrations were calculated from the absorbance at 280 nm using an absorbance value of 1.4 for a I mg/ml solution. For IgM containing bound PDT groups the absorbance at 280 nm was corrected for the contribution of the PDT group using a molar absorbance coefficient of 5 100 M-'*cm-'.
Characterization of polymeric carriers
Molecular weights of PBLG (M,, M,) were dete~ined by HP-SEC/LALLS using DMF as the eluent at a flow rate of 1 .O ml/min. The HP-SEC unit, consisting of a Waters model 6000A pump and a Waters U6K injector, was connected to three Waters PStyragel ( 105, 1 04, 1 O3 A) columns (7.8 x 300 mm) in series. The column eluate was monitored by a Chromatix KMX-6 LALLS apparatus and a Waters R 4 10 differential refractometer. Refractive index increments (d&de) at 633 nm were dete~ined using a modified Brice-Phoenix BP-ZOO~V differential refractometer. The dnfdc value of PBLG in DMF was 0.1113 ml/g.
The average molecular weight of PGA (M,) was determined by intrinsic viscosity measurements in 0.19 M NaCl, 10 mM sodium phosphate, pH 7.3, using an Ubbelohde capillary dilution viscometer or capillary micro-viscometer at 25 "C. The PGA molecular weight was calculated from the intrinsic viscosity [q ] and the re-
The amount of residual benzylester groups in PGA was determined from the UV spectra of solutions of PGA sodium salt in water using molar absorbance coefficients of 290 M-' -cm-' at 267 nm [lo] .
The content of tyrosinamide in polymeric conjugates was calculated from the absorbance at 275 nm in 0.1 M sodium phosphate buffer, pH 7.0, using a molar absorbance coefficient of 1400 M-' cm-' and from the absorbance at 287 nm in the same buffer adjusted to pH 12 with 1 M NaOH using a molar absorbance coefficient of 1900 M-' *cm-I. Corrections were made for the contribution of polymer-bound PDT groups by using PDT-PGA and PGA prepared by triethylamine-initiated polymerization of BLG NCA f 101 as controls. The values of the tyrosinamide content determined at either 275 or 287 nm were identical.
The content of polymer-bound PDT groups is expressed as pmol/g.
Polyacrylamide gel electrophoresis (PAGE)
SDS-PAGE was performed in a V16 vertical gel electrophoresis system (BRL, U.S.A.). Proteins were separated in a linear gradient gel (T=4-26%, C=3%) with a spacer (T=3%, C= 3%) using the discontinuous buffer system of Laemmli [22] . The thickness of the gel was 1.5 mm. Electrophoresis was carried out for 13-15 h at 15 mA at ambient temperature. After electrophoresis, gels were fixed by immersion in a solution of trichloroacetic acid ( 120 g/l) for 90 min at ambient temperature and were subsequently stained for 24 h by immersion in a solution containing Serva Blue G-250 f 1 g/l ), am= monium sulfate (60 g/l> and phosphors acid (20 ml/l). The gels were then soaked for 24 h in aqueous methanol (250 ml/l) in order to remove excess dye sol particles. The protein-dye complexes were fixed in a solution of ammonium sulfate ( 50 g/l),
Western blot of SDS-polyacrylamide gels
Proteins were transferred from the gel onto Immobilon@ membranes by electrophoresis in a Transblot cell (Biorad, USA) using 25 mM TrisHCl, 0.192 M glycine, 200 ml/l methanol, 300 mg/l SDS as transfer buffer. Blotting was carried out for 2 h at 10 V/cm and 0.25 A at ambient temperature, the membrane being placed at the anodal side of the gel. After electroblotting the individual lanes were cut out and were fractionated as indicated in Fig. 8 . Counting of membrane species was carried out with a y-counter (Packard 5530).
Synthetic procedures
BLG NCA
Syntheses of N-carboxyanhydrides
were performed in a hood. Phosgene present in solutions to be discarded was decomposed by adding concentrated ammonia.
The reaction was performed in a 1 1 pear-shaped flask supplied with a reflux condenser and a drying tube containing CaCl,. Triphosgene
[23] (10.0 g, 38.0 mmol) was added to a suspension of BLG (20.5 g, 86.4 mmol) in THF (200 ml) under vigorous stirring at room temperature.
The mixture was subsequently stirred for 1 h at 5 5 'C. The resulting clear lightly yellow solution was evaporated to dryness in vacua. The yellow oil was dissolved in THF (200 ml) and hexanes (mixed isomers; 330 ml) were added gradually with stirring until the onset of crystallization. The mixture was then kept in the freezer (-18 "C ) overnight. The white crystals were isolated by filtration and were washed with hexanes, maintaining an atmosphere of nitrogen. The product was recrystallized twice from THF/hexanes ( 100 ml/ 120 ml) in the same manner and was finally dried in a stream of nitrogen. Yield 14.0 g (62%) of BLG NCA,m.p. 90-91.5"C (96-97°C [22] ).
Bis-PGA-cystamine
A solution of cystamine-free base (0.123 g, 0.79 mmol, ratio monomer/initiator 48 mole/ mole) in dioxane ( 12.9 ml) was added with stirring to a solution of BLG NCA (10.0 g, 38.0 mmol) in dioxane (240 ml). After 24 h, a sample (0.25 g) was taken and the amount of BLG NCA was determined by titration with sodium methoxide in methanol using thymol blue as the indicator [ 241 indicating 95% conversion of the monomer. The viscous solution was poured into ethanol (4 1) with vigorous stirring. The precipitate was isolated by filtration, washed with ethanol and dried in vacua at room temperature using KOH pellets as a drying agent to give 7.0 g (84%) of a mixture of PBLG and bis-PBLG-cystamine [ 3 1.
The crude polymer (6.7 g, 30.6 mmol) was dissolved in a mixture of anisole (9.8 ml) and TFA (54 ml) with stirring. After 1 h the solution was placed in an ice bath and MSA (54 ml) was added. The mixture was stirred for 20 min at 0" C and for 25 min at 20' C. The solution was poured into diisopropylether (1.2 1) with stirring. The white precipitate was isolated by filtration, washed with diisopropylether and dried by suction. The product was dissolved in water (250 ml) by adding NaHCOj (2.5 g) and Na,HPO, (5 g) until pH 7.5. The solution was filtered (0.45 pm, Millipore type HA) and was dialyzed exhaustively against water. The solution was lyophilized yielding 3.68 g (79.4%) of a mixture of bis-PGA cystamine, sodium salt, and PGA, sodium salt. The 'H NMR spectrum in D20 was consistent with the structure. The amount of residual benzyl groups was 0.3 mole % as determined by UV spectroscopy.
PD T-PGA
Nitrogen was bubbled through a solution of bis-PGA-cystamine, sodium salt, ( 1.80 g) in buffer III ( 105 ml) for 15 min. DTT (0.272 g, 1.8 mmol) was added and the solution was stirred for 2 h at 45°C. After cooling to room temperature the solution was acidified to pH 2 by the addition of 6 N HCl. The suspension of the gel precipitate was centrifuged ( 3000 rpm, 10 min ) and the clear supernatant was discarded. The gel precipitate was resuspended in 0.01 M HCl (3 x 70 ml ) and water ( 3 x 70 ml ) each time followed by centrifugation. The gel precipitate was dissolved in water (60 ml) with stirring by adding Na2HP0, (2.1 g ) and NaOH to adjust the pH to 8.0, maintaining an atmosphere of nitrogen. The pH of the solution was then adjusted to 6.0 and TPS (80 ml in buffer V) was added. The mixture was left to stand for 2 days at room temperature. The TPS gel was transferred to a glass filter and the gel was washed successively with buffer V (5x200 ml), buffer IV (5 x200 ml) and buffer III (5 x 200 ml). The filtrates obtained were each acidified to pH 2.0 with 6 N HCI yielding a gel precipitate for both the buffer V and buffer IV washings. On acidification of the buffer III washings to pH 2, no precipitate was formed indicating that all PGA not bound to TPS had been removed by the prior washings in buffer V and IV. The gel precipitate from the buffer V and buffer IV washings was isolated by centrifugation and was resuspended in 0.01 N HCl (3x 100 ml) and water (2x 100 ml) each time followed by centrifugation. The suspension of the polymer gel in water was finally lyophilized yielding 0.45 g (30%) of PGA, H-form.
Buffer III (90 ml) and 2-mercaptoethanol ( 16 ml) were added to the TPS gel containing bound PGA and the mixture was left to stand for 4 days at room temperature. The TPS gel was transferred to a glass filter and the gel was washed with buffer III ( 5 x 200 ml). The filtrates were combined and the solution was acidified to pH 2.0 with 6 N HCI. The polymer precipitate was collected by centrifugation and was washed several times with 0.0 1 N HCl. The polymer precipitate was dissolved in a mixture of buffer VII (50 ml) and buffer VI ( 50 ml). The polymer solution was added slowly to a solution prepared by mixing a solution of PDS (570 mg) in ethanol (50 ml) with 0.10 M sodium phosphate, pH 7.0 ( 100 ml ) and the mixture was stirred for 2 days at room temperature. The organic solvent was removed by rotary evaporation in vacua and the solution was filtered. The clear filtrate was dialyzed exhaustively against water at 4°C. The solution was filtered (0.20 pm, Millipore, type HA) and was lyophilized yielding 232 mg ( 13W) of PDT-PGA, sodium salt.
D~rivatizat~o~ of PGA and PHEG with tyro~~namide
A solution of PDT-PGA, sodium salt (240 mg, 1.59 mmol) in water (24 ml) was added dropwise with stirring to 0.1 N HCl (100 ml). The mixture was centrifuged (3000 rpm, 10 min) and the gel precipitate was resuspended in 0.0 1 N HCl (2 x 100 ml) and water ( LOO ml ) each time followed by centrifugation. A suspension of the gel precipitate in water was lyophilized yielding PDT-PGA, H-form ( 164 mg, 80%).
Derivatization of PGA.
To a solution of PDT-PGA, H-form, ( 160 mg) in DMF (2 ml) were successively added a solution of H-TyrNH* (0.025 mmol) in DMF (0.1 ml) and EEDQ (0.0297 mmol) in DMF (0.0594 ml). The mixture was stirred for 2 days at room temperature. The resulting gel was dissolved in 0.25 M sodium phosphate buffer, pH 7.3 (20 ml) and liltered ( 0.45 p ) . The solution was divided in two equal parts which were added dropwise with stirring to 0.1 N HCl ( 100 ml). The gel precipitates were washed with 0.01 N WC1 and water followed by centrifugation as described above.
One batch of the gel precipitate was dissolved in 0.25 M sodium phosphate, pH 7.3, and dialyzed against water for 4 days at 4°C. The solution was filtered (0.45 m, Millipore type HA) and was lyophilized yielding PDT-PGA-TyrNH,, sodium salt (86.2 mg, 90%).
Derivatization of PHEG.
The other batch of the gel precipitate was resuspended in water ( 100 ml) and lyophilized yielding PDT-PGA-TyrNH*, H-form (77.2 mg, 94%). To a stirred solution of this polymer in DMF ( 1.5 ml) were successively added saccharin ( 133 mg, 0.73 mmol) and CDI (136 mg, 0.84 mmol). After 30 min 2-aminoe-than01 (0.072 ml, 1.19 mmol) was added. The mixture was stirred for 24 h at room temperature, mixed with 0.25 M sodium phosphate buffer, pH 7.3 (20 ml), acidified with solid sodium dihydrogen phosphate to pH 7.3 and stirred for 4 h. After centrifugation of insoluble material the solution was dialyzed against 3% NaCl (3 days) and water (3 days) at 4°C. The solution was filtered (0.45 ,um, Millipore type HA) and lyophilized yielding PDT-PHEG-TyrNH2 (76.3 mg, 73%). Amino acid analysis after acidic hydrolysis: Glu, 1 .OO; 2-aminoethanol, 1.08; Tyr, 0.0 16; peptide content 80%.
Fractionation ofPGA and PHEG derivatives by SEC. Both tyrosinamide-substituted polymers were fractionated by gel filtration on a TSK Fraktogel HW-55s column (95 x 2.6 cm; 500 ml) equilibrated in 0.1 M NaCl, 10 mM sodium phosphate, pH 7.0. PDT-PGA-TyrNH2 was dissolved in the equilibration buffer and, prior to chromatography, was dialysed against this buffer for 24 h with several changes of buffer in order to prevent exclusion of the polyelectrolyte from the gel due to electrostatic effects. PDT-PHEGTyrNH, was dissolved in the phosphate buffer and was applied directly on the column. Elution took place at a flow rate of 35 ml/h and the UV absorbance of the eluate was monitored at 206 nm. Fractions of 6 ml were collected and were pooled to a 'high molecular weight' (HMW) and 'low molecular weight' (LMW) polymer fraction which were dialyzed against water at 4" C and then lyophilized. The separation of the crude polymers into fractions of different molecular size was confirmed by HP-SEC on a Zorbax GF 450 column equilibrated in 0.20 M sodium phosphate buffer, pH 7.0, at a flow rate of 1.0 ml/min. The UV absorbance of the eluate was monitored at 226 nm or 280 nm.
Radiolabelling of IgM 16.88 and TyrNH,-substituted polymers
Radio-iodination was carried out following the iodogen labelling procedure. Proteins and polymers were incubated with Na13'I (IgM 16.88) or Na'251 (polymers) in vials coated with 500 pg iodogen for 30 min at 0' C. Excess non-bound reagents were removed by gel filtration on prepacked Sephadex G-25 columns (PDlO, Pharmacia, Sweden) equilibrated in PBS.
Plasma stability of '251-labelled polymers
Unfractionated '251-labeled carriers PDT-PGA and PDT-PHEG were incubated for 1 h at 37 'C and for various periods of time up to 72 h at 20" C in murine plasma. Samples were analyzed by GPC on Zorbax GF-450 as described above. Fractions of 1 ml were collected and radioactivity was measured with a y-counter (Packard 5530). Subsequently, the reaction mixtures were applied on a column of TSK Fraktogel HW-55s (75x 5 cm; 1500 ml) equilibrated in PBS. Elution took place with PBS as eluent at a flow rate of 100 ml/h. The UV absorbance of the column eluate was monitored at 280 nm. Fractions containing the immunoconjugates were pooled and the combined fractions were concentrated to a final protein concentration of around 3 mg/ml by ultrafiltration on Amicon YM 10. The solutions were sterilized by filtration through a 0.22 pm (Millex GV, Millipore, U.S.A.) membrane.
Preparation of doubly labelled immunoconjugates of IgM
Biodistribution of labeled IgM 16.88, polymers and immunoconjugates in mice
150 ~1 of solutions containing the doubly labelled immunoconjugates or single-labelled parent compounds at concentrations varying from 0.6-3 mg/ml of PBS were injected i.v into the tail vein of mice followed by injection of 50 ~1 of PBS in order to minimize the loss of labelled compound by bleeding. Per compound, groups of nine mice were used. At 2, 6 and 24 h after administration, groups of 3 mice per compound were sacrificed. The following tissues were collected: kidneys, without fat and adrenals; liver with gall-bladder; spleen; femur-bone; muscle tibialis anterior; thyroid together with the surrounding cartilage. Blood was collected by aorta puncture under ether-anaesthesia.
Urine was collected by bladder punction. Blood, urine and tissues except the thyroid were weighed, and radioactivity was determined with a well-type Ycounter (Packard 5530). The '25I activity was measured after the decay of the ' 3 'I activity. The activity found in blood, urine and tissues is expressed as % of the dose administered per gram of tissue. For the thyroid the activity is expressed as % of the dose administered.
Results
Preparation of PGA with terminal thiol groups
Thiol-PGA was prepared by the method described by Kate et al. [ 3 ] in which the thiol group is introduced at the C-terminal polymer end (Fig.  1, Table 1 ). A solution of BLG NCA in dioxane ( 4 wt% ) was polymerized using cystamine as the initiator (A/I 48 mole/mole).
The polymer which was obtained in a yield of 84% is a mixture of PBLG and bis-PBLG-cystamine etic acid in the presence of anisole to scavenge benzyl cations. The mixture of PGA and bis-PGA-cystamine thus obtained was isolated in a yield of 79% relative to the benzyl-protected polymer. The polyacid was treated with DTT to reduce polymer-bound disullide groups and thiol-PGA was isolated using covalent chromatography on TPS. Thiol-PGA was converted to the PDT-derivative by treatment with PBS. PDT-PGA was obtained in a yield of 13% (batch 1) or 17% (batch 2 ) relative to crude PGA (Table  1) . These yields are lower than the yield of 3 1% found previously [ 3 1. Analysis of the content of PDT groups showed values of 21.2 pmol/g (batch 1) and 23.4 pmol/g (batch 2) from which M, values of 40300 (DP, 3 12) (batch 1) and 36300 (DP, 283 ) (batch 2 ) were calculated.
PGA not bound by TPS was isolated in yields of 30% (batch 1) and 5 1% (batch 2 ) . The PDT content of the polymer batches was found to be 6.7-6.8 pmol/g. The presence of PDT groups in this PGA fraction indicates that in the disulfide exchange between thiol-PGA and Sepharose- bound 2-pyridyldithio groups the 2-pyridyl moiety is transferred to PGA besides the normally expected formation of disulfide-linked PGA-Sepharose.
Preparation and fractionation of TyrNH,-substitoted polymers
In order to enable labelling of the polymers with radioactive iodine, PGA and PHEG were substituted to a low degree with TyrNHz (Fig. 2 , 'From UV absorbance at 275 nm at pH 7 and at 288 nm at pH 12; *From amino acid analysis after acidic hydrolysis. Table 2 ). TyrNH, was linked via the amino group with a part of the carboxyl groups of PDT-PGA in DMF using EEDQ as the coupling agent similar to the procedure developed by us for the coupling of ADR and PGA [ lo] . Part of this conjugate was reacted with 2-aminoethanol using saccharin/CD1 activation in DMF [ lo] to fully convert the carboxyl side chains into 2-hydroxyethylamide groups. The TyrNHz content of PDT-PGA was 1.7 mol% and that of PDT-PHEG was around 1.5 mol%. This level of substitution is supposed not to affect the general physicochemical properties of the polymers. Gel liltration of the crude PDT-PGA and PDT-PHEG preparations of TSK Fraktogel HW-55s revealed a very broad molecular weight range from apparent values of 1.5 x 1 O3 to 60 kDa (Fig. 3 ) . In order to facilitate later purification of immunoconjugates of IgM 16.88 from non-conjugated polymers, only those fractions of PGA and PHEG with an apparent molecular weight below 440 kDa (ferritin), designated LMW (Fig. 3) , were used for immunoconjugation. These LMW fractions contained polymers with an apparent molecular mass between 760 and 160 kDa (PGA) or between 590 and 40 kDa (PHEG) as was determined from the midpoints of the elution curves obtained by HP-SEC on Zorbax GF 450 (Fig. 4) . The overall yield of PDT-PGA and PDT-PHEG after gel filtration on Fraktogel HW55s was excellent; for both polymers a total recovery of over 95% was found.
Preparation of doubly labelled immunoconjugates of IgM 16.88 and PGA or PHEG
The route of preparation of the immunoconjugate of IgM 16.88 and PHEG is given by way of example in Fig. 5 . Prior to immunoconjugation, IgM 16.88 was labelled with i3'I and the LMW fractions of PDT-PGA and PDT-PHEG with 1251 using the iodogen procedure. Both the antibody and polymers showed identical elution 67 profiles in HP-SEC on Zorbax GF 450 before and after radiolabelling indicating that unwanted side effects, which may have led to crosslinking, had not taken place (data not shown). 13'I-labelled IgM 16.88 was reacted with SPDP to yield a PDT substitution ratio of 16 moles of PDT per mole of antibody. This substitution level has no effect on the immunoreactivity of IgM 16.88 (E. Bos et al., unpublished results). PDT-activated antibody was added to either of the two '251-labelled polymers in which thiol groups had been liberated through incubation with DTT. The immunoconjugates obtained were fractionated by gel filtration on TSK Fraktogel HW-55s (Fig. 6) . Because of their increased molecular weight, the immunoconjugates should elute in front of the non-conjugated IgM which is eluted between 620 and 800 ml (Fig. 6 ) and non-conjugated polymers which should elute between 700 and 1000 ml, based on the chromatographic behaviour presented above. Therefore, the UV-absorbing fractions eluting from the TSK Fraktogel HW 55s column between 520 and 650 ml were pooled as indicated (Fig. 6 ) as they were supposed not to contain any of the free parental compounds. HP-SEC analysis on Zorbax GF 450 of trial experiments on immunoconjugate preparations (Fig. 7) showed elution profiles of the compounds very similar to those observed with TSK Fraktogel HW 55s.
The doubly labelled immunoconjugates were subjected to SDS-PAGE and Western blotting on Immobilon@ membranes (Figs. 8-11 ) . Fractionation and counting of "'I and '25I activity revealed, that both labels were present in the first two fractions (Figs 9 and 10 ; cf. Fig. 11) indicating that a proper immunoconjugate had been formed. Since no 13iI activity could be detected in fractions 3 and 4 of the immunoconjugates (Fig. 9) , it was concluded that these preparations were devoid of free IgM. However, in spite of careful pooling after gel filtration a substantial amount of '25I activity ( Fig. 10; cf. Fig. 11 ) was found in the lower molecular weight range showing the presence of non-conjugated PGA and PHEG. Possibly, these free polymers were attached to the antibody or immunoconjugate via PDT-PGA-TyrNH* and PDT-PHEG-TyrNH2 before (crude) and after (HMW, LMW) preparative SEC (Fig. 3) .
non-covalent interactions and could not be regates but it may well account for up to 35% of moved properly under non-denaturing condithe total '25I activity. tions. Since we do not know the transfer efticiency during blotting and the binding efficiency of Immobilon membranes for the individual compounds it is difficult to estimate the amount of free polymer present in the immunoconju-
Plasma stability of '251-labelled PDT-PGA and
PDT-PHEG
The stability of unfractionated '251-labelled PDT-PGA and PDT-PHEG in murine plasma was analyzed by HP-SEC on a Zorbax GF 450 column. As is shown in Fig. 12 , no significant shift of radioactivity towards the low molecular weight area was observed for incubation periods up to 72 h, indicating that both polymers were stable for that period of time. Thus, the biodistribution studies of PGA and PHEG and the immunoconjugates will not be complicated by biodegradation of the polymers and a concomitant change in pharmacokinetic behaviour.
Biodistribution of antibody, polymers and immunoconjugates in mice
From the data presented in Fig. 13 , a striking difference between the pharmacokinetic behaviour of PGA and its uncharged derivative PHEG can be observed. PGA was cleared rapidly from the circulation at a t1,2B of less than 2 h and was taken up by liver and spleen to an appreciable extent, while its metabolisation results in a high accumulation of radiolabel in kidneys and secretion in urine on short term and an elevated uptake of iodide in the thyroid gland after 24 h. The blood clearance of PHEG was much slower than was found for PGA, the t,,28 being approximately 10 h, which was attended by a substan- tially lower uptake of the polymer in RES organs.
From the results it is concluded that the polyanionic character of PGA has a major impact on the biodistribution of the molecule and leads to a high uptake in liver and spleen as was predicted from the results obtained with pyran copolymer [ 15 1.
As can be seen in Fig. 14, the biodistribution of both immunoconjugates, which was derived only from the 1311 label on the antibody, is not affected by the polymer moiety as it is almost indistinguishable from that of the non-conjugated antibody. Antibody and immunoconjugates are cleared from the circulation at a relatively high rate, the t1,28 being around 6 h, and are accu- mulating in an early phase in liver and spleen, Also in this case, the high uptake in thyroid after 24 h reflects the dehalogenation and metabolisation of the compounds injected. Since no difference in spleen uptake between free IgM and conjugates is observed, we may conclude that the immunoconjugates are devoid of large amounts of aggregates. The data on half-life in the circulation correspond quite well with previously published results where IgM 16.88 was administered to nude mice bearing tumour xenografts [51.
Discussion
Monoclonal antibodies directed to tumour-associated antigens have been found to accumulate in tumours when administered in human patients [ 43 1. This phenomenon allows in vivo diagnosis with the aid of y-emitting isotopes attached to these antibodies and creates a possibility for targeted therapy with (x-or /3-emitting isotopes or cytostatic compounds [ 1, 2, 4, 5, 25 I.
For optimal efficacy of these so-called radioimmunoconjugates and chemo-immunoconjugates an adequate biodistribution that allows a specific and high tumour uptake, an appropriate residence time of conjugates at the tumour site allowing the delivery of sufficient radiation dose or the release of sufficient drug, and the possibility of repeated administration are of major importance. The human MoAb IgM 16.88 shows potential for targeted therapy on the basis of its properties including the extent of tumour localization and the enhanced residence time at the tumour [ 4 1. Due to binding of this antibody to necrotic areas in the tumour [ 41, we aim at the use of toxic compounds with a field effect, e.g. Pemitting isotopes or drugs bound to the antibody through acid-labile linkers where the drug is re- (R) . The proteins were stained by Serva Blue G-250. "'1 or "'1 activity offractions 1-12 (left) in Western blots was counted leased at the tumour site rather than on or in the tumour cell. In order to deliver a therapeutically effective dose of cytostatic drugs at the tumour with the set of human MoAbs available, we are obliged to use an intermediate drug carrier for which PGA and the neutral derivative PHEG were possible candidates. In order to test the applicability of these polymers in targeted drug therapy immunoconjugates of human IgM 16.88 and PGA or PHEG were synthesized and purified and were subjected to a biodistribution study. PGA and PHEG are degradable by proteolytic enzymes [ 26-301. The rate of enzyme-mediated main chain cleavage of PGA is low at pH 7-8 and is maximal at pH 5 [25, 26] . This has been cor-71 related with the pH-dependent equilibrium between the unordered conformation of PGA when anionically charged and the a-helical conformation of PGA in the acid form with a pH midpoint of 5 [ 26,271. PHEG is degradable by various enzymes at neutral pH [ 28-301. For the use of these polymers as drug carriers in immunoconjugates, it is essential that cleavage of the main chain does not occur in the circulation and that the polymer remains intact for a reasonable time at the tumour. The data presented here indicate that the size distribution of PGA and PHEG is unaltered after incubation in murine plasma for periods up to 72 h and that the amount of low molecular weight material does not exceed a few percent. So, it is concluded that the polymers either free or bound to IgM 16.88 remain stable after i.v. administration in mice during the period of the biodistribution experiments.
Since the broad size distribution of the polymers hampered purification of immunoconjugates by SEC, LMW fractions of which the elution started at about the same volume as that of free IgM, were used as starting material for immunoconjugation.
The observation that polymers with a molecular mass below 50 kDa have an apparent molecular weight in the order of 320 kDa (/3-galactosidase) in SEC, can be explained by the fact that PGA and PHEG are randomly coiled polymers in aqueous solution [ 3 1,321. This implies that the volume occupied by the polymer chains may be similar to that of highmolecular weight proteins which are relatively compact due to secondary and tertiary structures.
In spite of the fact that the elution profiles of the immunoconjugates suggested a complete separation from free antibody and polymer, SDS-PAGE demonstrated the presence of significant amounts of free polymers indicating that a noncovalent interaction of polymer and immunoconjugate had taken place during the coupling reaction. So, the removal of residual polymer by SEC may be improved by elution under slightly denaturing conditions which do not affect the immunoreactivity of the antibody. The presence of the free polymers, however, prevented us from analysing the in vivo stability hindered disulfide bridge between IgG and the toxin moiety. At any rate, the absence of free IgM allowed us to study biodistribution of IgM-polymer conjugates through the 13iI label of the antibody. The similarity in biodistribution of immunoconjugates and free IgM as described in this paper may look surprising in view of the pharmacokinetic properties of free PGA and PHEG which were shown to be quite different. However, it has to be kept in mind that the polymers account for only lo-15% of the total mass in immunoconjugates assuming an average of three polymer chains per antibody molecule, a number that is usually found for immunoconjugates of IgM and HSA at a comparable PDT-substitution of the antibody (E. Bos et al., unpublished results ) .
An important conclusion can be drawn, i.e. that the antibody molecule is the major determinant in the process of biodistribution. From this point of view, PGA as well as PHEG may be used as intermediate drug carriers in immunoconjugates. Since the attachment of the highly charged PGA molecule to an antibody was found to have a major impact on the physicochemical properties of the immunoconjugate in spite of its minor ~ont~bution to the mass, it might be advantageous to use PHEG as carrier instead, as the uncharged character of this derivative may be less dominant over those of the antibody, thus facilitating purification methods other than SEC, e.g. ion-exchange chromatography or hydrophobic interaction chromato~aphy. At present we focus on the synthesis and purification of immunoconjugates using PHEG as carrier and adriamycin as cytostatic drug which is coupled to the polymer via acid-labile bonds.
Conclusions
( 1) The biodistribution of IgM 16.88 and immunoconjugates of IgM 16.88 with either PGA or PHEG are similar. ( 2 ) Both PGA and PHEG seem useful as drug carrier in immunoconjugates. ( 3 ) Removal of unbound polymers from immunoconjugates is difficult probably due to complex formation between polymers and immunoconjugates. (4) PHEG seems promising as a carrier for release of drug in the circulation due to high blood levels, slow clearance and low RES uptake.
